ID: ALA321740

Max Phase: Preclinical

Molecular Formula: C41H49N3O6

Molecular Weight: 679.86

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccccc1N1CCN(CCC(Oc2ccc(NC(=O)c3ccccc3OCCCC(=O)O)cc2)c2ccc(CC(C)C)cc2)CC1

Standard InChI:  InChI=1S/C41H49N3O6/c1-30(2)29-31-14-16-32(17-15-31)37(22-23-43-24-26-44(27-25-43)36-10-5-7-12-39(36)48-3)50-34-20-18-33(19-21-34)42-41(47)35-9-4-6-11-38(35)49-28-8-13-40(45)46/h4-7,9-12,14-21,30,37H,8,13,22-29H2,1-3H3,(H,42,47)(H,45,46)

Standard InChI Key:  UGTTXMJFJCQFGL-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 679.86

Molecular Weight (Monoisotopic): 679.3621

AlogP: 7.72

#Rotatable Bonds: 17

Polar Surface Area: 100.57

Molecular Species: ACID

HBA: 7

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.79

CX Basic pKa: 7.95

CX LogP: 5.16

CX LogD: 5.07

Aromatic Rings: 4

Heavy Atoms: 50

QED Weighted: 0.11

Np Likeness Score: -0.88

References

1. Yoshida K, Horikoshi Y, Eta M, Chikazawa J, Ogishima M, Fukuda Y, Sato H..  (1998)  Synthesis of benzanilide derivatives as dual acting agents with alpha 1-adrenoceptor antagonistic action and steroid 5-alpha reductase inhibitory activity.,  8  (21): [PMID:9873656] [10.1016/s0960-894x(98)00538-1]

Source

Source(1):

• Scientific Literature